Added to Your Shopping Cart
Certificate of Analysis
Are you looking for...
You might be interested in...
Type in Product name, Keyword or Catalog number to see suggestions.
Looking for a Certificate of Analysis?
Have your catalog and lot numbers ready and click the link.
Find CoA
Need help? Please contact us
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 25 Million Cells
Human CD34+ Progenitor Cells from Mobilized Peripheral Blood, Positive Selection, 25 Million Cells
Catalog #: 4Y-101F
Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood using positive immunomagnetic selection containing ≥ 25 million cells
Product Overview
Mobilized peripheral blood CD34+ Hematopoietic stem and progenitor cells are positively selected using a direct immunomagnetic CD34 microbead labeling system. Cells are cryopreserved in Lonza Cryo Media in a cryovial. Cell purity is determined post thaw using a FACS assay. Count and viability is determined using AO/PI. Cells are collected from healthy donors following IRB protocols.
Manufactured by AllCells®
Request More InfoBenefits
- Obtain large quantities of CD34+ from a donor
- Certificate of analysis (CoA) provided for each lot purchased
- Test negative for mycoplasma, bacteria, yeast, and fungi
- HIV-1, Hepatitis B and Hepatitis C are not detected for all donors and/or cell lots
Applications
- CAR-T therapy development
- iPSC generation
- Autoimmune disease
- Immunology
- Cancer research
Storage and Content
1 x Cryopreserved ampule of Human CD34+ Progenitor Cells from Mobilized Peripheral Blood containing ≥ 25 million cellsSDS, CoA, and Instructions
Safety Data Sheets (SDS)
Choose a language to view the SDS.
Certificate of Analysis (CoA)
Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.
Educational Material
Brochures, White Papers etc.
-
Instructions and Technical Sheet- Human CD34+ Cells
-
CD34+ Cells for Cell and Gene Therapy Process Development
In this interview Dr. Manon Destalminil, Bioprocessing Project Leader at CellProthera, discusses the advantages of using research-grade CD34+ cells for cell and gene therapy process development. Please register to read.
